U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H24N4O2S
Molecular Weight 396.506
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIRABEGRON

SMILES

NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1

InChI

InChIKey=PBAPPPCECJKMCM-IBGZPJMESA-N
InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1

HIDE SMILES / InChI
Molecular Formula C21H24N4O2S
Molecular Weight 396.506
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/?term=20878594

Mirabegron (trade name Myrbetriq in the US and Betmiga in Europe) is a drug for the treatment of overactive bladder (OAB). It was developed by Astellas Pharma and was approved in the United States in July 2012. Originally developed as a treatment for diabetes, the development of mirabegron was later refocused to OAB. Mirabegron is an orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities. Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niche is associated with the development of MPNs.

CNS Activity

CNS Non-penetrant
1018
Curator's Comment: Mirabegron has a low propensity to cross the blood–brain barrier

Originator

Approval Year

2012
614
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2637
 22.4 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8307
MYRBETRIQ

Approved Use

Indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Launch Date

1.34084166E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12.8 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000ClinPharmR.pdf
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIRABEGRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
29.4 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/25791612
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIRABEGRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
177 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000ClinPharmR.pdf
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIRABEGRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
46.82 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/25791612
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIRABEGRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
41.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000ClinPharmR.pdf
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIRABEGRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
28.1 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/25791612
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIRABEGRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
29%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000ClinPharmR.pdf
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIRABEGRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
https://pubmed.ncbi.nlm.nih.gov/24178236
healthy, 23.6 years (range: 20–27 years)
n = 8
Health Status: healthy
Age Group: 23.6 years (range: 20–27 years)
Sex: M
Population Size: 8
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
https://pubmed.ncbi.nlm.nih.gov/24178236
Other AEs: Pulse rate increased...
Other AEs:
Pulse rate increased (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
https://pubmed.ncbi.nlm.nih.gov/24178236
400 mg single, oral
Highest studied dose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/24178236
healthy, 23.8 years (range: 20–27 years)
n = 6
Health Status: healthy
Age Group: 23.8 years (range: 20–27 years)
Sex: M
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/24178236
Sources:
https://pubmed.ncbi.nlm.nih.gov/24178236
200 mg 1 times / day multiple, oral
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
unhealthy, 58.0±13.7 years
n = 167
Health Status: unhealthy
Condition: overactive bladder
Age Group: 58.0±13.7 years
Sex: M+F
Population Size: 167
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
Other AEs: Cardiac disorders, Eye disorders...
Other AEs:
Cardiac disorders (3%)
Eye disorders (3.6%)
Constipation (1.8%)
Dyspepsia (2.4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Disc. AE: Constipation, Hypertension...
AEs leading to
discontinuation/dose reduction:
Constipation (0.2%)
Hypertension (0.2%)
Tachycardia (0.1%)
Atrial fibrillation (0.5%)
Palpitations (0.5%)
Edema peripheral (0.5%)
Pyrexia (0.5%)
ALT increased (0.4%)
AST increased (0.4%)
Bilirubin increased (0.4%)
Liver enzyme abnormal (0.4%)
Hypertensive crisis (0.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
AEs

AEs

AESignificanceDosePopulation
Pulse rate increased 2%
200 mg 1 times / day multiple, oral
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
https://pubmed.ncbi.nlm.nih.gov/24178236
healthy, 23.6 years (range: 20–27 years)
n = 8
Health Status: healthy
Age Group: 23.6 years (range: 20–27 years)
Sex: M
Population Size: 8
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
https://pubmed.ncbi.nlm.nih.gov/24178236
Constipation 1.8%
200 mg 1 times / day multiple, oral
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
unhealthy, 58.0±13.7 years
n = 167
Health Status: unhealthy
Condition: overactive bladder
Age Group: 58.0±13.7 years
Sex: M+F
Population Size: 167
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
Dyspepsia 2.4%
200 mg 1 times / day multiple, oral
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
unhealthy, 58.0±13.7 years
n = 167
Health Status: unhealthy
Condition: overactive bladder
Age Group: 58.0±13.7 years
Sex: M+F
Population Size: 167
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
Cardiac disorders 3%
200 mg 1 times / day multiple, oral
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
unhealthy, 58.0±13.7 years
n = 167
Health Status: unhealthy
Condition: overactive bladder
Age Group: 58.0±13.7 years
Sex: M+F
Population Size: 167
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
Eye disorders 3.6%
200 mg 1 times / day multiple, oral
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
unhealthy, 58.0±13.7 years
n = 167
Health Status: unhealthy
Condition: overactive bladder
Age Group: 58.0±13.7 years
Sex: M+F
Population Size: 167
Sources:
https://pubmed.ncbi.nlm.nih.gov/23471546/
Tachycardia 0.1%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Constipation 0.2%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Hypertension 0.2%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Hypertensive crisis 0.3%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
ALT increased 0.4%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
AST increased 0.4%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Bilirubin increased 0.4%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Liver enzyme abnormal 0.4%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Atrial fibrillation 0.5%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Edema peripheral 0.5%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Palpitations 0.5%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Pyrexia 0.5%
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
unhealthy, adult
n = 2736
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 2736
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf
Page: p. 300
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1670

inhibitor
1532
inhibitor
1695
substrate
1168

inhibitor
1789
inhibitor
1570

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1463

CYP2B6
770

CYP2C8
869

CYP2C19
1410

CYP2E1
846

P-gp
1401

OCT1
498

OCT2
630
P-gp
1491

UGT
183

BChE
1

OCT1
317

OCT2
336

OCT3
76

OATP1A2
59

OATP2B1
103

BCRP
545
CYP1A2
671

CYP3A
125
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1826
 moderate
yes (co-administration study)
Comment: Cmax and AUC of metoprolol increased by 90% and 229% and of desipramine by 79% and 241%, respectively; The Cmax and AUC of tamsulosin was increased by 60% when co-administered with mirabegron
Page: 27.0
CYP1A2
1620
 no
CYP3A
291
 no
CYP1A2
1620
 unlikely
CYP2B6
946
 unlikely
CYP2C19
1484
 unlikely
CYP2C8
923
 unlikely
CYP2C9
1747
 unlikely
CYP2E1
929
 unlikely
OCT1
513
 weak
OCT2
631
 weak
P-gp
1588
 weak
CYP3A4
1857
 weak
yes (co-administration study)
Comment: The Cmax and AUC of tamsulosin (a CYP2D6 and CYP3A4 substrate) was increased by 60% when co-administered with mirabegron
Page: 30.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1670
 major
yes (co-administration study)
Comment: Ketoconazole (inhibitor) increased the Cmax and AUC of mirabegron by 45% and 81%; rifampin (inducer) reduced the Cmax and AUC by 35% and 44%, respectively;
Page: 27.0
BChE
1
 minor
CYP2D6
1168
 minor
UGT
183
 minor
BCRP
545
 no
OATP2B1
103
 no
OATP1A2
59
 yes
OCT1
317
 yes
OCT2
336
 yes
OCT3
76
 yes
P-gp
1491
 yes
yes (co-administration study)
Comment: Ketoconazole (inhibitor) increased the Cmax and AUC of mirabegron by 45% and 81%; rifampin (inducer) reduced the Cmax and AUC by 35% and 44%, respectively;
Page: 27.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1603
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:65349
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:65349
MolPort
MolPort-019-994-262
https://www.molport.com/shop/molecule-link/MolPort-019-994-262
Selleck Chemicals
mirabegron-ym178
http://www.selleckchem.com/products/mirabegron-ym178.html
ZINC
ZINC000001996784
http://zinc15.docking.org/substances/ZINC000001996784
PubMed

PubMed

TitleDatePubMed
Beta3-adrenoceptors in human detrusor muscle.
2002 May
A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders.
2003 Aug
Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
2007 May
Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder.
2009 Dec
Pharmacotherapy of the overactive bladder.
2009 Oct
The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.
2013 May
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Patents

07342117
2
07982049
1
20050004190
1
20050101607
4

Sample Use Guides

In Vivo Use Guide
25 mg once daily, with or without food. 25 mg is effective within 8 weeks. Based on individual efficacy and tolerability, may increase dose to 50 mg once daily.
Route of Administration: Oral
In Vitro Use Guide
Mirabegron increased cAMP accumulation with EC(50) value = 19 nmol/L in CHO cells expressing rat β(3)-adrenoceptors.
Substance Class Chemical
Created
by admin
on Fri Dec 16 19:34:28 UTC 2022
Edited
by admin
on Fri Dec 16 19:34:28 UTC 2022
Record UNII
MVR3JL3B2V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIRABEGRON
DASH   INN   JAN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
MIRABEGRON [USAN]
Common Name English
YM178
Code English
mirabegron [INN]
Common Name English
4-THIAZOLEACETAMIDE, 2-AMINO-N-(4-(2-(((2R)-2-HYDROXY-2-PHENYLETHYL)AMINO)ETHYL)PHENYL)-
Systematic Name English
BETMIGA
Brand Name English
2-(2-Aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
Systematic Name English
YM-178
Code English
MYRBETRIQ
Brand Name English
MIRABEGRON [ORANGE BOOK]
Common Name English
BETANIS
Brand Name English
MIRABEGRON [MART.]
Common Name English
MIRABEGRON [VANDF]
Common Name English
MIRABEGRON [MI]
Common Name English
MIRABEGRON [JAN]
Common Name English
2-(2-AMINO-1,3-THIAZOL-4-YL)-N-(4-(2-(((2R)-2-HYDROXY-2-PHENYLETHYL)AMINO)ETHYL)PHENYL)ACETAMIDE
Systematic Name English
Mirabegron [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C48149
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
LIVERTOX NBK547887
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
NDF-RT N0000185008
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
WHO-VATC QG04BD12
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
WHO-ATC G04BD12
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
EMA ASSESSMENT REPORTS BETMIGA (AUTHORIZED: URINARY BLADDER, OVERACTIVE)
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
Code System Code Type Description
DRUG BANK
DB08893
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
INN
8907
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
PUBCHEM
9865528
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
LACTMED
Mirabegron
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
WIKIPEDIA
Mirabegron
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
ChEMBL
CHEMBL2095212
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
NDF-RT
N0000185007
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY Adrenergic beta3-Agonists [MoA]
EPA CompTox
DTXSID101021648
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
MERCK INDEX
M11690
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
FDA UNII
MVR3JL3B2V
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
JAPANESE REVIEW
BETANIS
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY APPROVED JUNE 2011
CAS
223673-61-8
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
USAN
WW-31
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
DAILYMED
MVR3JL3B2V
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
IUPHAR
7445
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
NDF-RT
N0000182137
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
EVMPD
SUB32690
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
CHEBI
65349
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
NCI_THESAURUS
C90633
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
RXCUI
1300786
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY RxNorm
DRUG CENTRAL
4382
Created by admin on Fri Dec 16 19:34:28 UTC 2022 , Edited by admin on Fri Dec 16 19:34:28 UTC 2022
PRIMARY
Related Record Type Details
BETA-3 ADRENERGIC RECEPTOR
TARGET -> AGONIST
SHORT-ACTING
Related Record Type Details
Structure of YM-9636324
METABOLITE -> PARENT
CYP 3A4 is the primary responsible isoenzyme for in vitro hepatic oxidative metabolism of mirabegron, with a minor role of CYP2D6
Structure of YM-9636324
METABOLITE -> PARENT
PLASMA; URINE
Structure of MIRABEGRON N-GLUCURONIDE
METABOLITE -> PARENT
PLASMA; URINE
Structure of ACTARIT
METABOLITE -> PARENT
URINE
Structure of YM-538853
METABOLITE -> PARENT
In vitro studies suggest a role for CYP2D6 and CYP3A4 in the oxidative metabolism of mirabegron
Structure of MIRABEGRON N-CARBAMOYLGLUCURONIDE
METABOLITE -> PARENT
PLASMA; URINE
Structure of MIRABEGRON O-GLUCURONIDE
METABOLITE INACTIVE -> PARENT
Structure of YM-538853
METABOLITE -> PARENT
PLASMA; URINE
Structure of YM-538858
METABOLITE INACTIVE -> PARENT
In vitro and ex vivo studies have shown the involvement of uridine diphospho-glucuronosyltransferases (UGT)
Structure of 2-((4-AMINOPHENETHYL)AMINO)-1-PHENYLETHANOL, (R)-
METABOLITE -> PARENT
PLASMA
Structure of 3-HYDROXY YM-208876 GLUCURONIDE
METABOLITE -> PARENT
URINE
Structure of YM-538858
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA; URINE
Structure of MIRABEGRON O-GLUCURONIDE
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA; URINE
Structure of YM-538852
METABOLITE -> PARENT
PLASMA; URINE
Related Record Type Details
Structure of 2-[[2-(4-Nitrophenyl)-ethyl]amino]-1-phenylethanol, (R)-
PARENT -> IMPURITY
Related Record Type Details
Structure of MIRABEGRON
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Structure of MIRABEGRON
Elimination
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966